Gilead's Kite, Appia Bio to Collaborate on Allogeneic Cell Therapies for Cancer
August 05 2021 - 9:07AM
Dow Jones News
By Colin Kellaher
Gilead Sciences Inc. on Thursday said its Kite unit signed a
collaboration and license agreement with biotechnology startup
Appia Bio Inc. to research and develop allogeneic cell therapies
for cancer.
The Foster City, Calif., biopharmaceutical company said Appia
would receive an upfront payment, an equity investment, and
additional milestone payments for a total value of up to $875
million, along with royalties on product sales.
Gilead said Appia, founded last year, is developing engineered
allogeneic cell therapies from hematopoietic stem cells for cancer
patients.
The company said Kite, a cancer immunotherapies company it
bought in late 2017 for nearly $12 billion, and Appia would develop
chimeric antigen receptor-engineered invariant natural killer T
cells using Appia's ACUA technology platform for allogeneic cell
therapy.
Gilead said Appia would be responsible for preclinical and early
clinical research of two product candidates engineered with
chimeric antigen receptors provided by Kite, which in turn would be
responsible for the development, manufacturing and
commercialization of the product candidates.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 05, 2021 09:02 ET (13:02 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024